Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Benzamides"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 1-20 z 273
Tytuł:
A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor.
Autorzy:
Agyemang A; Barts and The London School of Medicine and Dentistry, London, UK.
Farrell C; ICON Clinical Research, Marlow, UK.
Moore W; Mereo BioPharma Group plc, London, UK.
Parkin J; Mereo BioPharma Group plc, London, UK.
Pokaż więcej
Źródło:
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2021 Jan; Vol. 10 (1), pp. 30-39. Date of Electronic Publication: 2020 Dec 30.
Typ publikacji:
Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Models, Biological*
ATP Binding Cassette Transporter, Subfamily B, Member 1/*antagonists & inhibitors
Benzamides/*administration & dosage
Cytochrome P-450 CYP3A Inhibitors/*administration & dosage
Protein Kinase Inhibitors/*administration & dosage
Pyrazoles/*administration & dosage
p38 Mitogen-Activated Protein Kinases/*antagonists & inhibitors
Administration, Oral ; Adult ; Anti-Bacterial Agents/administration & dosage ; Azithromycin/administration & dosage ; Benzamides/adverse effects ; Benzamides/blood ; Benzamides/pharmacokinetics ; Cross-Over Studies ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Drug Interactions ; Humans ; Itraconazole/administration & dosage ; Itraconazole/adverse effects ; Male ; Middle Aged ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/blood ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrazoles/adverse effects ; Pyrazoles/blood ; Pyrazoles/pharmacokinetics ; Verapamil/administration & dosage
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Development of a dried blood spot sampling method towards therapeutic monitoring of radotinib in the treatment of chronic myeloid leukaemia.
Autorzy:
Lee J; Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Jung SY; Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Choi MY; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
Park JS; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
Park SK; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
Lim SA; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
Cho KH; Analytical Research Group, Drug Development Service Division, Biocore Co. Ltd., Seoul, Korea.
Oh SY; Analytical Research Group, Drug Development Service Division, Biocore Co. Ltd., Seoul, Korea.
Ha J; Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Kim DW; Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.; Department of Hematology, Catholic Hematology Hospital, Leukemia Research Institute, The Catholic University of Korea, Seoul, Korea.
Lee J; Department of Pharmacy, College of Pharmacy, Seoul National University, Seoul, Korea.; Research Institute of Pharmaceutical Sciences, Seoul National University, Seoul, Korea.
Pokaż więcej
Źródło:
Journal of clinical pharmacy and therapeutics [J Clin Pharm Ther] 2020 Oct; Vol. 45 (5), pp. 1006-1013. Date of Electronic Publication: 2020 Feb 05.
Typ publikacji:
Comparative Study; Journal Article; Validation Study
MeSH Terms:
Benzamides/*administration & dosage
Dried Blood Spot Testing/*methods
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Pyrazines/*administration & dosage
Adult ; Aged ; Benzamides/pharmacokinetics ; Chromatography, High Pressure Liquid/methods ; Drug Monitoring/methods ; Female ; Humans ; Male ; Middle Aged ; Protein Kinase Inhibitors/pharmacokinetics ; Pyrazines/pharmacokinetics ; Reproducibility of Results ; Tandem Mass Spectrometry/methods ; Young Adult
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Autorzy:
Badillo M; University of Texas MD Anderson Cancer Center.
Nava D; University of Texas MD Anderson Cancer Center.
Rosa M; University of Texas MD Anderson Cancer Center.
Chen W; University of Texas MD Anderson Cancer Center.
Guerrero M; University of Texas MD Anderson Cancer Center.
Wang M; University of Texas MD Anderson Cancer Center.
Pokaż więcej
Źródło:
Clinical journal of oncology nursing [Clin J Oncol Nurs] 2020 Aug 01; Vol. 24 (4), pp. 392-398.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents*/adverse effects
Benzamides*/adverse effects
Lymphoma, Mantle-Cell*/drug therapy
Pyrazines*/adverse effects
Protein Kinase Inhibitors/*adverse effects
Adult ; Clinical Trials, Phase II as Topic ; Humans
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Momelotinib: an emerging treatment for myelofibrosis patients with anemia.
Autorzy:
Chifotides HT; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX, 77030, USA.
Bose P; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX, 77030, USA.
Verstovsek S; Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, 1400 Holcombe Blvd., Houston, TX, 77030, USA. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2022 Jan 19; Vol. 15 (1), pp. 7. Date of Electronic Publication: 2022 Jan 19.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms:
Anemia/*drug therapy
Benzamides/*therapeutic use
Primary Myelofibrosis/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*therapeutic use
Anemia/complications ; Anemia/metabolism ; Clinical Trials as Topic ; Humans ; Primary Myelofibrosis/complications ; Primary Myelofibrosis/metabolism ; Signal Transduction/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synthesis, In Vitro and In Silico Anticancer Activity of New 4-Methylbenzamide Derivatives Containing 2,6-Substituted Purines as Potential Protein Kinases Inhibitors.
Autorzy:
Kalinichenko E; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 5/2 Academician V.F. Kuprevich Street, BY-220141 Minsk, Belarus.
Faryna A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 5/2 Academician V.F. Kuprevich Street, BY-220141 Minsk, Belarus.
Bozhok T; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 5/2 Academician V.F. Kuprevich Street, BY-220141 Minsk, Belarus.
Panibrat A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, 5/2 Academician V.F. Kuprevich Street, BY-220141 Minsk, Belarus.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 Nov 25; Vol. 22 (23). Date of Electronic Publication: 2021 Nov 25.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Benzamides/*chemistry
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Protein Kinases/*chemistry
Purines/*chemistry
Antineoplastic Agents/chemistry ; Apoptosis ; Cell Cycle ; Cell Proliferation ; Computer Simulation ; Dose-Response Relationship, Drug ; Humans ; In Vitro Techniques ; Molecular Docking Simulation ; Molecular Structure ; Neoplasms/pathology ; Protein Kinase Inhibitors/chemistry ; Structure-Activity Relationship ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignancies.
Autorzy:
Collins GP; NIHR Oxford Biomedical Research Center, Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, UK.
Clevenger TN; Acerta Pharma, South San Francisco, CA, USA.
Burke KA; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Yang B; Acerta Pharma, South San Francisco, CA, USA.
MacDonald A; Clinical Pharmacology & Safety Sciences, Oncology R&D, AstraZeneca, Cambridge, UK.
Cunningham D; Gastrointestinal and Lymphoma Unit, Royal Marsden and Institute of Cancer Research Biomedical Research Centre, London, UK.
Fox CP; Department of Clinical Haematology, Nottingham University Hospitals NHS Trust and Division of Cancer and Stem Cells, University of Nottingham, Nottingham, UK.
Goy A; Department of Medicine, John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Gribben J; Department of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Roschewski M; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Vose JM; Division of Hematology/Oncology, University of Nebraska Medical Center, Omaha, NE, USA.
Vallurupalli A; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, USA.
Cheung J; Acerta Pharma, South San Francisco, CA, USA.
Raymond A; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Nuttall B; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Stetson D; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Dougherty BA; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Schalkwijk S; Clinical Pharmacology & Safety Sciences, Oncology R&D, AstraZeneca, Cambridge, UK.
Carnevalli LS; BioScience, Oncology R&D, AstraZeneca, Cambridge, UK.
Willis B; BioScience, Oncology R&D, AstraZeneca, Boston, MA, USA.
Tao L; Biometrics, Oncology R&D, AstraZeneca, South San Francisco, CA, USA.
Harrington EA; Translational Science, Oncology R&D, AstraZeneca, Cambridge, UK.
Hamdy A; Acerta Pharma, South San Francisco, CA, USA.
Izumi R; Acerta Pharma, South San Francisco, CA, USA.
Pease JE; Oncology Business Unit, AstraZeneca, Cambridge, UK.
Frigault MM; Translational Medicine, Oncology R&D, AstraZeneca, Boston, MA, USA.
Flinn I; Sarah Cannon Center for Blood Cancer, Nashville, TN, USA.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2021 Nov; Vol. 62 (11), pp. 2625-2636. Date of Electronic Publication: 2021 Jul 16.
Typ publikacji:
Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Neoplasm Recurrence, Local*
Protein Kinase Inhibitors*/therapeutic use
B-Lymphocytes ; Benzamides ; Humans ; Morpholines ; Pyrazines ; Pyrimidines
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Design, Synthesis, and Biological Evaluation of Pyridineamide Derivatives Containing a 1,2,3-Triazole Fragment as Type II c-Met Inhibitors.
Autorzy:
Xiong H; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Cheng J; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Zhang J; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Zhang Q; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Xiao Z; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Zhang H; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Tang Q; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Zheng P; School of Pharmacy, Jiangxi Science & Technology Normal University, Nanchang 330013, China.
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2019 Dec 18; Vol. 25 (1). Date of Electronic Publication: 2019 Dec 18.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Design*
Benzamides/*chemistry
Benzamides/*pharmacology
Protein Kinase Inhibitors/*chemistry
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins c-met/*chemistry
Triazoles/*chemistry
Benzamides/chemical synthesis ; Cell Cycle ; Cell Line, Tumor ; Chemistry Techniques, Synthetic ; Humans ; Models, Molecular ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synthesis, Biological Activities and Docking Studies of Novel 4-(Arylaminomethyl)benzamide Derivatives as Potential Tyrosine Kinase Inhibitors.
Autorzy:
Kalinichenko E; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Faryna A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Kondrateva V; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Vlasova A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Shevchenko V; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. vas_.
Melnik A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. al_.
Avdoshko O; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Belko A; Institute of Bioorganic Chemistry, National Academy of Sciences of Belarus, BY-220141 Minsk, Belarus. .
Pokaż więcej
Źródło:
Molecules (Basel, Switzerland) [Molecules] 2019 Sep 30; Vol. 24 (19). Date of Electronic Publication: 2019 Sep 30.
Typ publikacji:
Journal Article
MeSH Terms:
Chemistry Techniques, Synthetic*
Molecular Docking Simulation*
Molecular Dynamics Simulation*
Benzamides/*chemistry
Benzamides/*pharmacology
Protein Kinase Inhibitors/*chemistry
Protein Kinase Inhibitors/*pharmacology
Benzamides/chemical synthesis ; Binding Sites ; Cell Line, Tumor ; Dose-Response Relationship, Drug ; Drug Design ; Fusion Proteins, bcr-abl/antagonists & inhibitors ; Fusion Proteins, bcr-abl/chemistry ; Humans ; Hydrogen Bonding ; Molecular Structure ; Protein Binding ; Protein Kinase Inhibitors/chemical synthesis ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines.
Autorzy:
Liu J; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Hong J; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.; Biomedical Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Ahn KS; PDXen Biosystems Co , Daejeon , Republic of Korea.
Go J; PDXen Biosystems Co , Daejeon , Republic of Korea.
Han H; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Park J; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Kim D; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Park H; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Koh Y; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.; Biomedical Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Shin DY; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.; Biomedical Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Yoon SS; Cancer Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.; Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine , Seoul , Republic of Korea.; Biomedical Research Institute, Seoul National University College of Medicine , Seoul , Republic of Korea.
Pokaż więcej
Źródło:
Leukemia & lymphoma [Leuk Lymphoma] 2019 Oct; Vol. 60 (10), pp. 2532-2540. Date of Electronic Publication: 2019 Apr 05.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*
Aminopyridines/*pharmacology
Benzamides/*pharmacology
Burkitt Lymphoma/*metabolism
Extracellular Signal-Regulated MAP Kinases/*metabolism
Interleukin-6/*metabolism
Morpholines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrazoles/*pharmacology
Aminopyridines/therapeutic use ; Benzamides/therapeutic use ; Burkitt Lymphoma/drug therapy ; Burkitt Lymphoma/pathology ; Cell Line, Tumor ; Cell Survival/drug effects ; Drug Synergism ; Humans ; Morpholines/therapeutic use ; Pyrazoles/therapeutic use ; Signal Transduction/drug effects
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.
Autorzy:
Drusbosky LM; Guardant 360, 505 Penobscot Drive, Redwood City, CA, 94063, USA.
Dawar R; Division of Medical Oncology, Department of Internal Medicine, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Rodriguez E; Division of Medical Oncology, Department of Internal Medicine, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA.
Ikpeazu CV; University of Miami Sylvester Comprehensive Cancer Center, 8100 SW 10th Street, Ste 3310F, Plantation, FL, 33324, USA. .; Division of Medical Oncology, Department of Internal Medicine, University of Miami Miller School of Medicine, 1475 NW 12th Avenue, Miami, FL, 33136, USA. .
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2021 Aug 23; Vol. 14 (1), pp. 129. Date of Electronic Publication: 2021 Aug 23.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms:
Mutation*/drug effects
Antineoplastic Agents/*therapeutic use
Carcinoma, Non-Small-Cell Lung/*drug therapy
Lung Neoplasms/*drug therapy
Protein Kinase Inhibitors/*therapeutic use
Proto-Oncogene Proteins c-met/*genetics
Animals ; Benzamides/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Clinical Trials as Topic ; Humans ; Imidazoles/therapeutic use ; Lung Neoplasms/genetics ; Piperidines/therapeutic use ; Proto-Oncogene Proteins c-met/antagonists & inhibitors ; Pyrazines/therapeutic use ; Pyridazines/therapeutic use ; Pyrimidines/therapeutic use ; Triazines/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Design strategies, SAR, and mechanistic insight of Aurora kinase inhibitors in cancer.
Autorzy:
Sankhe K; Department of Pharmaceutical Chemistry, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Prabhu A; Department of Pharmaceutical Chemistry and Quality Assurance, Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Khan T; Department of Pharmaceutical Chemistry and Quality Assurance, Bhanuben Nanavati College of Pharmacy, Mumbai, India.
Pokaż więcej
Źródło:
Chemical biology & drug design [Chem Biol Drug Des] 2021 Jul; Vol. 98 (1), pp. 73-93. Date of Electronic Publication: 2021 May 15.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Antineoplastic Agents/*chemistry
Aurora Kinase A/*antagonists & inhibitors
Neoplasms/*drug therapy
Protein Kinase Inhibitors/*chemistry
Animals ; Antineoplastic Agents/pharmacology ; Azepines/chemistry ; Azepines/pharmacology ; Benzamides/chemistry ; Benzamides/pharmacology ; Drug Approval ; Drug Resistance ; Drug Screening Assays, Antitumor ; Flavones/chemistry ; Flavones/pharmacology ; Gene Expression Regulation ; Humans ; Indazoles/chemistry ; Indazoles/pharmacology ; Organophosphates/chemistry ; Organophosphates/pharmacology ; Protein Binding ; Protein Conformation ; Protein Kinase Inhibitors/pharmacology ; Pyrazoles/chemistry ; Pyrazoles/pharmacology ; Pyrimidines/chemistry ; Pyrimidines/pharmacology ; Quinazolines/chemistry ; Quinazolines/pharmacology ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Autorzy:
Ikeda Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Yasutake R; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Yuki R; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Saito Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Nakayama Y; Department of Biochemistry & Molecular Biology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2021 May 27; Vol. 22 (11). Date of Electronic Publication: 2021 May 27.
Typ publikacji:
Journal Article
MeSH Terms:
Aurora Kinase B/*antagonists & inhibitors
Cell Survival/*drug effects
Cyclin B1/*metabolism
Imidazoles/*pharmacology
Mitosis/*drug effects
Protein Kinase Inhibitors/*pharmacology
Pyrazines/*pharmacology
Benzamides/pharmacology ; Cell Cycle/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Proteolysis ; Quinazolines/pharmacology ; Receptor, IGF Type 1/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effects of FGFR Tyrosine Kinase Inhibition in OLN-93 Oligodendrocytes.
Autorzy:
Rajendran R; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Böttiger G; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Dentzien N; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Rajendran V; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Sharifi B; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Ergün S; Institute of Anatomy and Cell Biology, University of Würzburg, Koellikerstrasse 6, 97080 Würzburg, Germany.
Stadelmann C; Institute for Neuropathology, Clinic for Neurology, University Medical Center, 37075 Göttingen, Germany.
Karnati S; Institute of Anatomy and Cell Biology, University of Würzburg, Koellikerstrasse 6, 97080 Würzburg, Germany.
Berghoff M; Experimental Neurology, Department of Neurology, Justus Liebig University of Giessen, 35385 Giessen, Germany.
Pokaż więcej
Źródło:
Cells [Cells] 2021 May 25; Vol. 10 (6). Date of Electronic Publication: 2021 May 25.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Benzamides/*pharmacology
Benzimidazoles/*pharmacology
Multiple Sclerosis/*drug therapy
Piperazines/*pharmacology
Protein Kinase Inhibitors/*pharmacology
Pyrazoles/*pharmacology
Quinolones/*pharmacology
Receptor, Fibroblast Growth Factor, Type 1/*metabolism
Remyelination/*drug effects
Animals ; Cell Line ; Oligodendroglia ; Rats
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Topical Application of JAK1/JAK2 Inhibitor Momelotinib Exhibits Significant Anti-Inflammatory Responses in DNCB-Induced Atopic Dermatitis Model Mice.
Autorzy:
Jin W; Division of Dermatology, Department of Clinical Medicine, Medical College of Yanbian University, Yanji 133000, China. jinwenyu_.; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. jinwenyu_.
Huang W; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. .
Chen L; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. .
Jin M; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. .
Wang Q; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. .
Gao Z; State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China. .
Jin Z; Division of Dermatology, Department of Clinical Medicine, Medical College of Yanbian University, Yanji 133000, China. jinzh_.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2018 Dec 10; Vol. 19 (12). Date of Electronic Publication: 2018 Dec 10.
Typ publikacji:
Journal Article
MeSH Terms:
Anti-Inflammatory Agents/*therapeutic use
Benzamides/*administration & dosage
Benzamides/*therapeutic use
Dermatitis, Atopic/*drug therapy
Janus Kinase 1/*antagonists & inhibitors
Janus Kinase 2/*antagonists & inhibitors
Protein Kinase Inhibitors/*therapeutic use
Pyrimidines/*administration & dosage
Pyrimidines/*therapeutic use
Administration, Topical ; Animals ; Anti-Inflammatory Agents/pharmacology ; Benzamides/pharmacology ; Cytokines/pharmacology ; Dendritic Cells/drug effects ; Dendritic Cells/metabolism ; Dermatitis, Atopic/blood ; Dermatitis, Atopic/genetics ; Dermatitis, Atopic/pathology ; Dinitrochlorobenzene ; Disease Models, Animal ; Female ; Gene Expression Regulation/drug effects ; Immunoglobulin E/blood ; Janus Kinase 1/metabolism ; Janus Kinase 2/metabolism ; Male ; Mice, Inbred BALB C ; Mice, Inbred C57BL ; OX40 Ligand/metabolism ; Phosphorylation/drug effects ; Protein Kinase Inhibitors/pharmacology ; Pyrimidines/pharmacology ; RNA, Messenger/genetics ; RNA, Messenger/metabolism ; STAT Transcription Factors/metabolism ; Skin/pathology ; Thymic Stromal Lymphopoietin
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Design, synthesis and biological evaluation of 4-bromo-N-(3,5-dimethoxyphenyl)benzamide derivatives as novel FGFR1 inhibitors for treatment of non-small cell lung cancer.
Autorzy:
Xie Z; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Cheng D; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Luo L; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Shen G; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Pan S; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Pan Y; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Chen B; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Wang X; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Liu Z; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Zhang Y; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Ye F; a School of Pharmaceutical Sciences , Wenzhou Medical University , Wenzhou , Zhejiang , China.
Pokaż więcej
Źródło:
Journal of enzyme inhibition and medicinal chemistry [J Enzyme Inhib Med Chem] 2018 Dec; Vol. 33 (1), pp. 905-919.
Typ publikacji:
Journal Article
MeSH Terms:
Drug Design*
Antineoplastic Agents/*pharmacology
Benzamides/*pharmacology
Carcinoma, Non-Small-Cell Lung/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Protein-Tyrosine Kinases/*antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 1/*antagonists & inhibitors
Antineoplastic Agents/chemical synthesis ; Antineoplastic Agents/chemistry ; Apoptosis/drug effects ; Benzamides/chemical synthesis ; Benzamides/chemistry ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Cell Cycle Checkpoints/drug effects ; Cell Line, Tumor ; Cell Proliferation/drug effects ; Dose-Response Relationship, Drug ; Drug Screening Assays, Antitumor ; Humans ; Molecular Docking Simulation ; Molecular Structure ; Protein Kinase Inhibitors/chemical synthesis ; Protein Kinase Inhibitors/chemistry ; Protein-Tyrosine Kinases/metabolism ; Receptor, Fibroblast Growth Factor, Type 1/metabolism ; Structure-Activity Relationship
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Abnormally activated OPN/integrin αVβ3/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer.
Autorzy:
Fu Y; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Zhang Y; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Lei Z; Department of Genetics, School of Biology and Basic Medical Sciences, Medical College of Soochow University, Suzhou, 215123, People's Republic of China.
Liu T; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Cai T; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Wang A; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Du W; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.
Zeng Y; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.; Suzhou Key Laboratory for Respiratory Diseases, Suzhou, 215006, People's Republic of China.
Zhu J; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China.; Suzhou Key Laboratory for Respiratory Diseases, Suzhou, 215006, People's Republic of China.
Liu Z; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China. .; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China. .; Suzhou Key Laboratory for Respiratory Diseases, Suzhou, 215006, People's Republic of China. .
Huang JA; Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, 215006, People's Republic of China. huang_jian_.; Institute of Respiratory Diseases, Soochow University, Suzhou, 215006, People's Republic of China. huang_jian_.; Suzhou Key Laboratory for Respiratory Diseases, Suzhou, 215006, People's Republic of China. huang_jian_.
Pokaż więcej
Źródło:
Journal of hematology & oncology [J Hematol Oncol] 2020 Dec 07; Vol. 13 (1), pp. 169. Date of Electronic Publication: 2020 Dec 07.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Drug Resistance, Neoplasm*/drug effects
Carcinoma, Non-Small-Cell Lung/*drug therapy
Integrin alphaVbeta3/*metabolism
Lung Neoplasms/*drug therapy
Osteopontin/*metabolism
Protein Kinase Inhibitors/*pharmacology
Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Benzamides/pharmacology ; Benzamides/therapeutic use ; Carcinoma, Non-Small-Cell Lung/genetics ; Carcinoma, Non-Small-Cell Lung/metabolism ; Cell Line, Tumor ; ErbB Receptors/antagonists & inhibitors ; ErbB Receptors/genetics ; ErbB Receptors/metabolism ; Focal Adhesion Kinase 1/metabolism ; Gefitinib/pharmacology ; Gefitinib/therapeutic use ; Humans ; Lung Neoplasms/metabolism ; Male ; Mice, Inbred BALB C ; Mice, Nude ; Protein Kinase Inhibitors/therapeutic use ; Pyrazines/pharmacology ; Pyrazines/therapeutic use ; Signal Transduction/drug effects ; Sulfonamides/pharmacology ; Sulfonamides/therapeutic use
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Autorzy:
Heo SK; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 44033, Republic of Korea.
Noh EK; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea.
Yu HM; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 44033, Republic of Korea.
Kim DK; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 44033, Republic of Korea.
Seo HJ; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 44033, Republic of Korea.
Lee YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea.
Cheon J; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea.
Koh SJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea.
Min YJ; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea.
Choi Y; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea. .
Jo JC; Biomedical Research Center, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, 44033, Republic of Korea. .; Department of Hematology and Oncology, Ulsan University Hospital, University of Ulsan College of Medicine, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan, 44033, Republic of Korea. .
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2020 Dec 04; Vol. 20 (1), pp. 1193. Date of Electronic Publication: 2020 Dec 04.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Benzamides/*pharmacology
Cytarabine/*pharmacology
Leukemia, Myeloid, Acute/*pathology
Protein Kinase Inhibitors/*pharmacology
Pyrazines/*pharmacology
Animals ; Antimetabolites, Antineoplastic/pharmacology ; Apoptosis/drug effects ; Cell Cycle/drug effects ; Daunorubicin/pharmacology ; Drug Synergism ; HL-60 Cells ; Humans ; Idarubicin/pharmacology ; Leukemia, Myeloid, Acute/drug therapy ; Male ; Membrane Potential, Mitochondrial/drug effects ; Mice ; Mice, Nude ; Neoplasm Proteins/biosynthesis ; Neoplasm Proteins/genetics ; Neoplasm Proteins/physiology ; Random Allocation ; Single-Blind Method ; Specific Pathogen-Free Organisms ; Tumor Cells, Cultured
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative efficacy and tolerability of front-line treatments for newly diagnosed chronic-phase chronic myeloid leukemia: an update network meta-analysis.
Autorzy:
Tang L; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China.; Hubei clinical medical center of cell therapy for neoplastic disease, Wuhan, Hubei, China.
Zhang H; Instisute of Pancreatic Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1227 Jiefang road, Wuhan, 430022,, Hubei, China.
Peng YZ; Instisute of Orthopedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1227 Jiefang road, Wuhan, 430022,, Hubei, China.
Li CG; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China.; Hubei clinical medical center of cell therapy for neoplastic disease, Wuhan, Hubei, China.
Jiang HW; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China.; Hubei clinical medical center of cell therapy for neoplastic disease, Wuhan, Hubei, China.
Xu M; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China.
Mei H; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China. .; Hubei clinical medical center of cell therapy for neoplastic disease, Wuhan, Hubei, China. .; Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, Hubei, China. .
Hu Y; Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Road, Wuhan, 430022,, Hubei, China. dr_.; Hubei clinical medical center of cell therapy for neoplastic disease, Wuhan, Hubei, China. dr_.; Collaborative Innovation Center of Hematology, Huazhong University of Science and Technology, Wuhan, Hubei, China. dr_.
Pokaż więcej
Źródło:
BMC cancer [BMC Cancer] 2019 Aug 28; Vol. 19 (1), pp. 849. Date of Electronic Publication: 2019 Aug 28.
Typ publikacji:
Comparative Study; Journal Article
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Leukemia, Myeloid, Chronic-Phase/*drug therapy
Protein Kinase Inhibitors/*administration & dosage
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Benzamides/administration & dosage ; Benzamides/adverse effects ; Dasatinib/administration & dosage ; Dasatinib/adverse effects ; Dose-Response Relationship, Drug ; Female ; Humans ; Imatinib Mesylate/administration & dosage ; Imatinib Mesylate/adverse effects ; Male ; Network Meta-Analysis ; Protein Kinase Inhibitors/adverse effects ; Pyrazines/administration & dosage ; Pyrazines/adverse effects ; Pyrimidines/administration & dosage ; Pyrimidines/adverse effects ; Survival Analysis ; Treatment Outcome
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Synergistic Effects of Combination Therapy with AKT and mTOR Inhibitors on Bladder Cancer Cells.
Autorzy:
Kim H; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.; Division of Hematology-Oncology, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu 42601, Korea.
Lee SJ; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.; Division of Hematology-Oncology, Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul 07804, Korea.
Lee IK; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Min SC; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Sung HH; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Jeong BC; Department of Urology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Lee J; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Park SH; Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 Apr 18; Vol. 21 (8). Date of Electronic Publication: 2020 Apr 18.
Typ publikacji:
Journal Article
MeSH Terms:
Antineoplastic Agents/*pharmacology
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Cell Proliferation/*drug effects
Protein Kinase Inhibitors/*pharmacology
Proto-Oncogene Proteins c-akt/*antagonists & inhibitors
TOR Serine-Threonine Kinases/*antagonists & inhibitors
Urinary Bladder Neoplasms/*drug therapy
Apoptosis/drug effects ; Benzamides/pharmacology ; Cell Line, Tumor ; Cell Survival/drug effects ; Drug Resistance, Neoplasm/drug effects ; Drug Synergism ; Epithelial-Mesenchymal Transition/drug effects ; Humans ; Imidazoles/pharmacology ; Inhibitory Concentration 50 ; Morpholines/pharmacology ; Mutation ; Proto-Oncogene Proteins c-akt/metabolism ; Pyrimidines/pharmacology ; Pyrroles/pharmacology ; Quinolines/pharmacology ; Signal Transduction/drug effects ; TOR Serine-Threonine Kinases/metabolism ; Urinary Bladder Neoplasms/enzymology ; Urinary Bladder Neoplasms/genetics ; Urinary Bladder Neoplasms/metabolism
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures.
Autorzy:
Singer JW; CTI BioPharma Corp., Seattle, Washington, United States of America.; Elson Floyd College of Medicine, Washington State University, Seattle, Washington, United States of America.
Al-Fayoumi S; CTI BioPharma Corp., Seattle, Washington, United States of America.
Taylor J; CTI BioPharma Corp., Seattle, Washington, United States of America.
Velichko S; Eurofins Discovery, Phenotypic Services, Burlingame, California, United States of America.
O'Mahony A; Eurofins Discovery, Phenotypic Services, Burlingame, California, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2019 Sep 27; Vol. 14 (9), pp. e0222944. Date of Electronic Publication: 2019 Sep 27 (Print Publication: 2019).
Typ publikacji:
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Janus Kinase 2/*antagonists & inhibitors
Primary Myelofibrosis/*drug therapy
Protein Kinase Inhibitors/*pharmacology
Signal Transduction/*drug effects
Benzamides/pharmacology ; Bridged-Ring Compounds/pharmacology ; Cell Proliferation/drug effects ; Cells, Cultured ; Cytokines/immunology ; Cytokines/metabolism ; Healthy Volunteers ; Humans ; Inflammation Mediators/immunology ; Inflammation Mediators/metabolism ; Janus Kinase 2/immunology ; Janus Kinase 2/metabolism ; Nitriles ; Primary Cell Culture ; Pyrazoles/pharmacology ; Pyrimidines/pharmacology ; Pyrrolidines/pharmacology ; Sulfonamides/pharmacology ; Toxicity Tests
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 1-20 z 273

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies